29. Anti-inflammatory effects of tyrosine-hydroxylase (TH)-positive catecholamine producing cells in chronic arthritis

2013 ◽  
Vol 32 ◽  
pp. e8-e9
Author(s):  
Z. Jenei-Lanzl ◽  
S. Capellino ◽  
F. Kees ◽  
R.H. Straub
Keyword(s):  
Tyrosine Hydroxylase ◽  
Chronic Arthritis ◽  
Anti Inflammatory

Effect of colchicine, methotrexate, and hydroxychloroquine therapy on cardiovascular outcomes in patients with calcium pyrophosphate crystal deposition disease

2021 ◽  
Vol 15 (6) ◽  
pp. 76-83
Author(s):  
M. S. Eliseev ◽  
E. V. Cheremushkina ◽  
O. V. Zhelyabina ◽  
M. N. Chikina ◽  
A. A. Kapitonova ◽  
...  
Keyword(s):  
Cardiovascular Events ◽  
Serum Uric Acid Level ◽  
Calcium Pyrophosphate ◽  
Chronic Arthritis ◽  
Cardiovascular Outcomes ◽  
Crystal Deposition ◽  
Crystal Deposition Disease ◽  
Deposition Disease ◽  
History Of ◽  
Anti Inflammatory

Anti-inflammatory therapy, such as colchicine (COL), has been suggested to affect the incidence of cardiovascular events in patients with calcium pyrophosphate crystal deposition disease (CPPD).Objective: to study the effect of anti-inflammatory therapy with COL, hydroxychloroquine (HC), and methotrexate (MT) on cardiovascular outcomes in patients with CPPD.Patients and methods. The study included 305 patients with CPPD, the majority (62.30%) were women. The average follow-up period was 3.9±2.7 years. Among factors influencing cardiovascular outcome were considered: gender; age; smoking; alcohol intake >20 conventional doses per week; arterial hypertension; a history of cardiovascular diseases (CVD), in particular ischemic heart disease, acute myocardial infarction, acute cerebrovascular accident, chronic heart failure >III stage according to NYHA, as well as type 2 diabetes mellitus (DM); body mass index >25 kg/m2 and >30 kg/m2; cholesterol level (CHOL) >5.1 mmol/l; glomerular filtration rate (GFR) < 60 ml/min/1.73 m2; serum uric acid level >360 μmol/l; hypercalcemia (serum calcium level >2.62 mmol/L); CRP level >2 mg/l; the presence of hyperparathyroidism (parathyroid hormone level >65 pg/ml); CPPD phenotypes (asymptomatic, osteoarthritis with calcium pyrophosphate crystals, chronic arthritis, acute arthritis); intake of COL, HC, MT, glucocorticoids and non-steroidal anti-inflammatory drugs (NSAIDs).Results and discussion. 264 patients were under dynamic observation. Any of the studied cardiovascular events were registered in 79 (29.9%) patients. During the observation period, 46 (17.4%) patients died, in 76.1% of cases the cause of death was CVD. Death from other causes was diagnosed in 11 (23.9%) patients. Non-fatal cardiovascular events were reported in 44 (16.7%) cases. The risk of cardiovascular events was higher in patients over 65 years of age (odds ratio, OR 5.97; 95% confidence interval, CI 3.33–10.71), with serum cholesterol levels ≥5.1 mmol/L (OR 1,95; 95% CI 1.04–3.65), GFR <60 ml/min/1.73 m2 (OR 2.78; 95% CI 1.32–5.56), history of CVD (OR 2,32; 95% CI 1.22–4.44). COL therapy reduced the risk of cardiovascular events (OR 0.20; 95% CI 0.11–0.39).Conclusion. Poor CVD outcomes in CPPD are associated with age, hypercholesterolemia, chronic kidney disease, and a history of CVD. The use of COL, in contrast to MT and HC, was accompanied by a decrease in cardiovascular risk.

Anti-inflammatory Activity of Taiwan Folk Medicine "Ham-Hong-Chho" in Rats

1995 ◽  
Vol 23 (03n04) ◽  
pp. 273-278 ◽  
Author(s):  
Hwa-Woei Chih ◽  
Chun-Ching Lin ◽  
Kung-Sheng Tang
Keyword(s):  
Folk Medicine ◽  
Chronic Arthritis ◽  
Complete Freund’S Adjuvant ◽  
Aqueous Extracts ◽  
Paw Edema ◽  
Bidens Pilosa ◽  
Freund’S Adjuvant ◽  
Complete Freund's Adjuvant ◽  
Freund's Adjuvant ◽  
Anti Inflammatory

"Ham-Hong-Chho" is a folk medicine in Taiwan, derived from the entire plants of Bidens pilosa L. var. minor (Blume) Sherff (Compositae), B. pilosa L. and B. chilensis DC. The anti-inflammatory effect of aqueous extracts of the three plants against paw edema induced by carrageenan and chronic arthritis induced by complete Freund's adjuvant were determined in rats. The results indicated that paw edema induced by carrageenan was significantly decreased by treatment with aqueous extracts (150 or 300 mg/kg) of all three plants ( p < 0.05) and that the effect of Bidens pilosa var. minor was the most potent. However, only extracts (500 mg/kg) of B. pilosa L. var. minor and B.pilosa L. significantly decreased the paw edema induced by complete Freund's adjuvant ( p < 0.05).

The Use of Rofecoxib (Vioxx) in the Treatment of Hemophilia.

Blood ◽  
2004 ◽  
Vol 104 (11) ◽  
pp. 3097-3097
Author(s):  
Benjamin N. Rattray ◽  
Diane J. Nugent ◽  
Guy Young
Keyword(s):  
Adjunctive Therapy ◽  
Joint Damage ◽  
Retrospective Chart Review ◽  
Chronic Arthritis ◽  
Bleeding Events ◽  
Safety And Efficacy ◽  
Chronic Synovitis ◽  
Cox 2 ◽  
Anti Inflammatory ◽  
Cox 2 Inhibitors

Abstract BACKGROUND: Joint hemorrhage and subsequent hemophilic arthropathy are significant complications in hemophilia. The pathophysiology of joint damage in such patients involves inflammation and angiogenesis. Cyclooxygenase 2 (COX-2) inhibitors are anti-inflammatory agents approved for use in osteoarthritis and rheumatoid arthritis and have potent anti-inflammatory, anti-angiogenic and analgesic properties yet do not affect platelet function in the manner of traditional NSAIDs. These properties make such agents potentially useful as adjunctive therapy in hemophiliacs. There is only one prior report of rofecoxib treatment in a single hemophiliac patient. METHODS: A retrospective chart review was conducted of all patients with hemophilia A or B seen at the Children’s Hospital of Orange County and treated with rofecoxib for acute hemarthrosis, chronic synovitis, target joint or pain. The safety and efficacy of rofecoxib treatment was determined based on information gathered from follow-up clinic visits, physical therapy examinations and nursing notes. Efficacy in hemarthrosis was determined by comparing consecutive bleeds treated without and with rofecoxib and judged subjectively as effective, partially effective or ineffective. Efficacy for chronic synovitis and pain was judged subjectively as above. Efficacy in resolution of target joints was judged as effective if the target joint resolved or ineffective if it did not resolve. RESULTS: A total of 30 patients between 3–40 years of age (26 FVIII deficiency, 4 FIX deficiency, 4 inhibitor patients) were treated for a total of 42 courses of rofecoxib treatment. All courses were evaluated for safety and 31 for efficacy. Rofecoxib was used for 8 acute hemarthroses, 4 target joints, 7 patients with chronic synovitis and 12 episodes of pain (see tables). Dosing regimens were chosen empirically. In most cases patients ≥ 10 years received 25 mg dose and children &lt; 10 years were given 12.5 mg. For pain, patients were treated as needed and for acute hemarthrosis, patients were treated for 5 days. For chronic synovitis, patients were treated daily for 30 days and continued indefinitely if improvement was noted. For target joints, patients were treated until resolution or until no response was noted. A total of 2 bleeding events were noted including a mouth bleed and an episode of hematuria. None of the events led to significant complications and all resolved. Treatment of acute hemarthrosis with factor alone versus factor and rofecoxib Efficacy Factor Alone Factor + rofecoxib Ineffective 1 (8%) 0 (0%) Partially Effective 3 (23%) 2 (25%) Effective 9 (69%) 6 (75%) Efficacy of rofecoxib in the management of target joints (along with factor therapy), chronic arthritis and pain in hemophilia patients Efficacy Target Joint Chronic Synovitis Pain Note: Efficacy judged subjectively by patient and physicians as ineffective, partially effective or effective. Target joints judged subjectively as ineffective or effective. Ineffective 2 (50%) 0 (0%) 0 (0%) Partially Effective N/A 2 (28.5%) 1 (8%) Effective 2 (50%) 5 (71.5%) 11 (92%) CONCLUSION: This is the largest study to date evaluating COX-2 inhibitors as adjunctive therapy in hemophilia. This study demonstrates that rofecoxib is safe and resulted in only 2 bleeding events that were mild and not definitively related to the medication. Importantly, it was found to be very effective in the management of chronic synovitis and joint pain. It may be useful as adjunctive therapy in the management of acute hemarthrosis and target joints. Further studies are needed to confirm both safety and efficacy.

scholarly journals Therapeutic Effects of Sodium Hyaluronate and Diclofenac Sodium in Chronic Arthritis

2019 ◽  
Vol 7 (4) ◽  
pp. 17-33
Author(s):  
Alsadek H Bogzil ◽  
Gamal Shams ◽  
Sohair Abd El-Latif
Keyword(s):  
Experimental Model ◽  
Diclofenac Sodium ◽  
Sodium Hyaluronate ◽  
Chronic Arthritis ◽  
Albino Rats ◽  
Therapeutic Effects ◽  
Monosodium Iodoacetate ◽  
Anti Inflammatory ◽  
Inflammatory Effect

The present study was designed to compare the anti-inflammatory effect of sodium hyaluronate, which is similar to the lubricant fluid that found naturally in the capsule of the healthy joint with diclofenac sodium, a member of NSAIDs commonly used in treatment of Osteoarthritis (OA), separately and in combination on an experimental model of osteoarthritis in rats induced by monosodium-iodoacetate (MIA). Twenty-five male albino rats weighing at the beginning of the experiment 160± 20 gm were used in this study. Rats were housed in cages at 25± 0.5°C. The rats were divided into 5 main groups.  

scholarly journals Systemic enzyme therapy with trypsin, bromelain and rutoside in the management of arthritis: an overview

2021 ◽  
Vol 7 (5) ◽  
pp. 1062
Author(s):  
Abhay P. Kulkarni ◽  
Himanshu A. Bendrey
Keyword(s):  
Proteolytic Enzymes ◽  
Joint Stiffness ◽  
Public Health Problem ◽  
Chronic Arthritis ◽  
Comparable Efficacy ◽  
Major Public Health Problem ◽  
Beneficial Effects ◽  
Anti Inflammatory ◽  
The Individual

<p class="abstract">Chronic arthritis, including osteoarthritis and rheumatoid arthritis, is a growing major public health problem leading to disability and reduced quality of life. Analgesic and anti-inflammatory drugs form the mainstay of treatment for chronic arthritis. The protracted use of the conventional medications for their management is fraught with shortcomings, including safety concerns. Proteolytic enzymes and antioxidant combinations have been used empirically, since ages, in many of these conditions. There is a growing body of evidence indicating the beneficial effects exerted by the individual ingredients and their combinations on the pathophysiology of arthritis. The analgesic, anti-inflammatory, anti-edematous, anti-thrombotic and anti-oxidant properties of these substances have been demonstrated in multiple in vitro and animal models. Furthermore, the therapeutic use of proteolytic enzyme-antioxidant combination is also supported by clinical trials in arthritis and related disorders. Such studies have mostly been carried out on preparations consisting of combinations of trypsin, bromelain and rutoside. The results of various studies (placebo-controlled and comparisons with nonsteroidal anti-inflammatory (NSAIDs) drugs) in patients with arthritis suggest that oral therapy with such enzyme-antioxidant combination produces improvement in all major clinical parameters like swelling, pain and joint stiffness and have comparable efficacy to NSAIDs. Some clinical studies also evaluated their effect on biochemical markers like cytokines, interferons and prostaglandins and reported remarkable improvements. The overall data also indicates that the tolerability of the enzyme-antioxidant combination is better than conventional therapies.</p>

scholarly journals e-Cadherin in 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-Induced Parkinson Disease

2016 ◽  
Vol 2016 ◽  
pp. 1-7 ◽  
Author(s):  
Samuela Cataldi ◽  
Michela Codini ◽  
Stéphane Hunot ◽  
François-Pierre Légeron ◽  
Ivana Ferri ◽  
...  
Keyword(s):  
Tyrosine Hydroxylase ◽  
Parkinson Disease ◽  
Interleukin 6 ◽  
Inflammatory Factor ◽  
Phosphatase And Tensin Homolog ◽  
Mesenchymal Transition ◽  
Caveolin 1 ◽  
Tensin Homolog ◽  
Anti Inflammatory ◽  
E Cadherin

Today a large number of studies are focused on clarifying the complexity and diversity of the pathogenetic mechanisms inducing Parkinson disease. We used 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), a neurotoxin that induces Parkinson disease, to evaluate the change of midbrain structure and the behavior of the anti-inflammatory factor e-cadherin, interleukin-6, tyrosine hydroxylase, phosphatase and tensin homolog, and caveolin-1. The results showed a strong expression of e-cadherin, variation of length and thickness of the heavy neurofilaments, increase of interleukin-6, and reduction of tyrosine hydroxylase known to be expression of dopamine cell loss, reduction of phosphatase and tensin homolog described to impair responses to dopamine, and reduction of caveolin-1 known to be expression of epithelial-mesenchymal transition and fibrosis. The possibility that the overexpression of the e-cadherin might be implicated in the anti-inflammatory reaction to MPTP treatment by influencing the behavior of the other analyzed molecules is discussed.

Anti-inflammatory effect of the ghrelin agonist growth hormone-releasing peptide-2 (GHRP-2) in arthritic rats

2005 ◽  
Vol 288 (3) ◽  
pp. E486-E492 ◽  
Author(s):  
Miriam Granado ◽  
Teresa Priego ◽  
Ana I. Martín ◽  
M. Ángeles Villanúa ◽  
Asunción López-Calderón
Keyword(s):  
Growth Hormone ◽  
Immune Cells ◽  
Peritoneal Macrophages ◽  
Chronic Arthritis ◽  
Gastrointestinal Hormone ◽  
Serum Concentrations ◽  
Anti Inflammatory ◽  
Nitrite Nitrate ◽  
Inflammatory Effect

Chronic arthritis induces hypermetabolism and cachexia. Ghrelin is a gastrointestinal hormone that has been proposed as a treatment to prevent cachexia. The aim of this work was to examine the effect of administration of the ghrelin agonist growth hormone-releasing peptide-2 (GHRP-2) to arthritic rats. Male Wistar rats were injected with Freund’s adjuvant, and 15 days later arthritic and control rats were daily injected with GHRP-2 (100 μg/kg) or with saline for 8 days. Arthritis induced an increase in serum ghrelin ( P < 0.01) and a decrease in serum concentrations of leptin ( P < 0.01), whereas GHRP-2 administration increased serum concentrations of leptin. GHRP-2 increased food intake in control rats but not in arthritic rats. However, in arthritic rats GHRP-2 administration ameliorated the external symptoms of arthritis, as it decreased the arthritis score (10.4 ± 0.8 vs. 13.42 ± 0.47, P < 0.01) and the paw volume. In addition, circulating IL-6 and nitrites/nitrates were increased by arthritis, and GHRP-2 treatment decreased the serum IL-6 levels ( P < 0.01). To elucidate whether GHRP-2 is able to modulate IL-6 release directly on immune cells, peritoneal macrophage cultures were incubated with GHRP-2 or ghrelin, the endogenous ligand of the growth hormone (GH) secretagogue receptor. Both GHRP-2 (10−7 M) and ghrelin (10−7 M) prevented endotoxin-induced IL-6 and decreased nitrite/nitrate release from peritoneal macrophages in vitro. These data suggest that GHRP-2 administration has an anti-inflammatory effect in arthritic rats that seems to be mediated by ghrelin receptors directly on immune cells.

Sign in / Sign up

Export Citation Format

Share Document